Healthcare / BiotechnologyNasdaqGM
$1.96
+0.01 (+0.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.9M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$84M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-108.6%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-20.2M · FCF $-18.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | $55180.00 | $140108.00 | $133928.00 | $28881.00 |
| Net Income | $-20.2M | $-20.2M | $-20.4M | $-22.3M | $-17.6M | $-13.9M | $-3.6M |
| EBITDA | $-18.6M | $-18.6M | $-20.3M | $-22.2M | $-17.7M | $-13.8M | $-3.5M |
| EPS | — | — | -0.89 | -1.71 | -1.48 | -1.37 | -1.33 |
| Operating Margin | — | — | — | -40328.3% | -12688.1% | -10323.6% | -12047.5% |
| Net Margin | — | — | — | -40354.3% | -12555.1% | -10371.7% | -12387.7% |
| Balance Sheet | |||||||
| Debt/Equity | 0.04 | 0.04 | 0.09 | 0.08 | 0.07 | 0.02 | 0.12 |
| Current Ratio | 4.69 | 4.69 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-18.5M | $-18.5M | $-18.9M | $-18.9M | $-14.8M | $-12.5M | $-3.3M |
| Returns | |||||||
| ROE | -108.6% | -108.6% | -278.1% | -177.0% | -93.2% | -39.9% | -57.7% |
| Valuation | |||||||
| P/B | 4.44 | 4.44 | 7.58 | 3.88 | 2.04 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | -60.6% | — | 363.7% | — |
| EPS Growth | — | — | 48.0% | -15.5% | — | -3.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.89 → n/d
Residual
+10.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.